JOINT TRANSNATIONAL CALL 2017:

"Translational Research on Rare Cancers"

PARTNER REQUEST/COLLABORATION OFFER

If you would like to have your profile published on the TRANSCAN-2 website, "Looking for a research partner" webpage, please fill out this form and send it to ✉
If you have any questions about this form, please do not hesitate to contact us at ✉

Note: Fields marked with a * are mandatory

Contact Information	
First name *	Juan R.
Last name *	de los Toyos
Position *	Tenured Senior Lecturer in Immunology
Telephone number	+34 985 106244
E-mail address*	jrtoyos@uniovi.es
Website address	
Institution/Organisation *	Universidad de Oviedo
Department*	Biología Funcional
Street	Julián Clavería s/n
Postal Code / City *	33006 Oviedo
Country *	Spain

***I agree with the publication of my contact data and of this form on the TRANSCAN-2 Website:**

☑ YES

SEARCH FOR A COLLABORATOR

IF YOU ARE LOOKING FOR A PARTNER IN YOUR SUGGESTED PROPOSAL, PLEASE SPECIFY ALSO THE NEEDED EXPERTISE

Project proposal
Project title (draft):
Short description of the project in preparation and of the consortium; description of the areas of expertise needed (Max. 2000 words):

OFFER FOR COLLABORATION

IF YOU PROPOSE YOURSELF AS A PARTNER IN A CONSORTIUM, PLEASE DETAIL YOUR EXPERTISE

Short description of the areas of interest and expertise (Max. 2000 words):

The *COL11A1* gene is differentially expressed in mesenchymal-type/ soft tissue human tumors such as rhabdomyosarcoma, chondrosarcoma, fibrosarcoma, osteosarcoma, or Ewing's sarcoma, as well as in solitary fibrous tumors.

This gene codes for the α1 chain of procollagen XIa1 -intracellular precursor- and of its mature extracellular-processed collagen XIa1.

The role of the *COL11A1* gene and the validation and biological significance of its protein expression in soft tissue tumors have not been examined in detail.

As biological tools, antibodies are very useful for characterization, diagnosis and therapy of human cancers. We aim to develop antibodies to the extracellular mature form of human collagen X1α1 and/or to other malignancy-associated targets, and we are wishing to collaborate with basic and translational research groups interested in exploring and analysing the diagnostic and/or therapeutic usefulness of such antibodies.